Shockwave (SWAV) Reports IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. WYFI
6. STUB
7. EAT
8. BTGO
9. NVDA
10. GO

Go back to Shockwave (SWAV) Reports IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years

Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years

May 19, 2022 8:20 AM EDT

SANTA CLARA, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation... More